Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsRetained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Achieve Life Sciences (ACHV) Short-term Investments (2016 - 2026)

Achieve Life Sciences (ACHV) has disclosed Short-term Investments for 13 consecutive years, with $1.2 million as the latest value for Q1 2026.

  • Quarterly Short-term Investments fell 88.36% to $1.2 million in Q1 2026 from the year-ago period, while the trailing twelve-month figure was $1.2 million through Mar 2026, down 88.36% year-over-year, with the annual reading at $15.5 million for FY2025, 28.38% down from the prior year.
  • Short-term Investments for Q1 2026 was $1.2 million at Achieve Life Sciences, down from $15.5 million in the prior quarter.
  • The five-year high for Short-term Investments was $46.6 million in Q2 2024, with the low at $1.2 million in Q1 2026.
  • Average Short-term Investments over 3 years is $18.5 million, with a median of $15.8 million recorded in 2025.
  • The widest YoY moves for Short-term Investments: up 28.38% in 2025, down 92.43% in 2025.
  • Achieve Life Sciences' Short-term Investments stood at $21.6 million in 2024, then fell by 28.38% to $15.5 million in 2025, then tumbled by 92.3% to $1.2 million in 2026.
  • Per Business Quant, the three most recent readings for ACHV's Short-term Investments are $1.2 million (Q1 2026), $15.5 million (Q4 2025), and $16.2 million (Q3 2025).